SIRPA and acute myeloid leukemia: However, further studies with larger sample sizes are necessary to better define the prognostic value of CD47 in patients with AML and, possibly, to identify a subgroup of patients who could derive maximum benefit from emerging CD47-SIRPα blocking therapies as a precision medicine approach.